Pharmaceutical composition for treating spleen deficiency and dampness accumulation type adult atopic dermatitis

Abstract

The invention relates to a traditional Chinese medicine composition for treating spleen deficiency and dampness accumulation type adult atopic dermatitis, the medicine composition is composed of active ingredients and medically acceptable auxiliary materials, and the active ingredients are prepared from the following raw material medicines in percentage by weight: 19-28% of astragalus membranaceus, 8-11% of roasted rhizoma atractylodis macrocephalae, 19-28% of rhizoma smilacis glabrae, 8-11% of cynanchum paniculatum, 6-9% of cortex dictamni, 6-9% of fructus alpiniae oxyphyllae and 9-14% of poria with hostwood. And 6-9% of mangnolia officinalis. The pharmaceutical composition disclosed by the invention has a remarkable effect on treating spleen deficiency and dampness accumulation type adult atopic dermatitis.

Description

Technical Field

[0001] This invention relates to medical preparations, specifically to pharmaceutical preparations containing undetermined structures derived from traditional Chinese medicine, which are suitable for treating adult atopic dermatitis of the spleen-deficiency and dampness-retention type. Background Technology

[0002] Atopic dermatitis (AD) is a common, chronic, relapsing inflammatory skin disease, often accompanied by impaired skin barrier function and abnormal immune responses. Its pathogenesis is closely related to multiple factors, including genetics, immunity, environment, diet, and lifestyle. Clinical manifestations mainly include pruritus, erythema, papules, exudation, and lichenification. The rash is commonly distributed on the face, neck, elbows, popliteal fossa, and trunk. The distribution of skin lesions varies among patients of different ages; adults often present with chronic lichenified patches. Atopic dermatitis has a long course, recurrent flare-ups, and significant itching, severely impacting sleep and quality of life. Some patients may also have other allergic diseases such as asthma and allergic rhinitis.

[0003] Modern medicine believes that the etiology of atopic dermatitis is mainly related to skin barrier dysfunction, immune abnormalities, and environmental stimuli. Genetic factors, such as mutations in the filaggrin gene, lead to damage to the skin barrier, making the skin more susceptible to invasion by allergens, microorganisms, and irritants, thereby inducing an inflammatory response. Immunological studies show that patients with atopic dermatitis often have Th2 cell activation and overexpression of inflammatory factors such as IL-4 and IL-13, resulting in elevated IgE levels and chronic inflammatory responses. External factors such as dust mites, pollen, food allergies, climate change, and mental stress can all induce or aggravate the condition.

[0004] Modern medical treatment for atopic dermatitis can be divided into two main categories: local treatment and systemic treatment. Local treatment refers to topical medications, such as local moisturizers, topical corticosteroids, calcineurin inhibitors, and phosphodiesterase 4 (PDE4) inhibitors. Systemic treatment includes oral antihistamines and the use of immunosuppressants such as cyclosporine. In recent years, targeted biologics targeting inflammatory pathways such as IL-4 and IL-13 (such as dupilumab) have also been widely used in the treatment of atopic dermatitis.

[0005] Traditional Chinese medicine (TCM) categorizes atopic dermatitis under the terms "four-bend wind" and "blood wind sores," believing that its occurrence is often due to inherent constitutional intolerance, coupled with dietary imbalances, emotional distress, and external pathogenic factors, leading to the invasion of pathogenic heat into the skin. In later stages, this damages body fluids, causing dryness and resulting in persistent rashes and itching. TCM treatment emphasizes syndrome differentiation and treatment based on the specific syndrome pattern, selecting targeted prescriptions and medications to alleviate symptoms and reduce recurrence.

[0006] Regarding common TCM syndrome types of atopic dermatitis, only some consensus statements or textbooks mention them, and no high-level guidelines have yet been published. The "Expert Consensus on Clinical Pathways for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Atopic Dermatitis (2024 Edition)" divides atopic dermatitis into three stages (hereinafter referred to as the "Expert Consensus"). In the subacute stage, syndromes such as spleen deficiency with dampness accumulation and liver stagnation with spleen deficiency are observed. For the former, recommended prescriptions include Chushi Weiling Decoction. However, the textbook "Traditional Chinese Medicine Dermatology and Venereology" in higher education of TCM proposes syndrome types such as heart and spleen heat accumulation, heart fire and spleen deficiency, and spleen deficiency with dampness accumulation. For spleen deficiency with dampness accumulation, the recommended prescription is "Xiao'er Huashi Decoction." Since the textbook does not provide a specific prescription, based on literature, it is inferred that this prescription refers to an empirical formula created by the TCM dermatology expert Zhu Renkang, whose components are Atractylodes lancea, Atractylodes macrocephala, Citrus reticulata peel, Poria cocos, Alisma plantago-aquatica, roasted malt, and Liu Yi San.

[0007] The expert consensus recommends the following formula for dispelling dampness and clearing heat: Atractylodes lancea, Magnolia officinalis, Citrus reticulata peel, Polyporus umbellatus, Alisma plantago-aquatica, Poria cocos, Atractylodes macrocephala, Talcum, Saposhnikovia divaricata, Gardenia jasminoides, Akebia trifoliata, Cinnamomum cassia, Glycyrrhiza uralensis, and Juncus effusus. While its dampness-clearing and heat-reducing effects are strong, it lacks spleen-tonifying and qi-boosting herbs, thus failing to address the pathogenesis of "spleen deficiency." The "Children's Dampness-Clearing Decoction" recommended in textbooks has the same problem: it focuses too much on eliminating dampness and not enough on tonifying the spleen.

[0008] The inventors believe that atopic dermatitis, especially in adulthood, is often characterized by "spleen deficiency and dampness accumulation," and that spleen deficiency is an important reason why the disease persists into adulthood. However, there is currently no drug composition specifically for adult atopic dermatitis. Summary of the Invention

[0009] The technical problem to be solved by the present invention is to provide a pharmaceutical composition for treating adult atopic dermatitis of the spleen deficiency and dampness type. The pharmaceutical composition is simple and effective, and has a significant effect on treating adult atopic dermatitis of the spleen deficiency and dampness type.

[0010] The technical solution of the present invention to solve the above problems is as follows:

[0011] A pharmaceutical composition for treating adult atopic dermatitis of the spleen-deficiency and dampness-retention type, the pharmaceutical composition comprising an active ingredient and medically acceptable excipients, wherein the active ingredient is made from the following raw material in weight percentages:

[0012] Astragalus membranaceus 19-28%, stir-fried Atractylodes macrocephala 8-11%, Smilax glabra 19-28%, Cynanchum paniculatum 8-11%, Dictamnus dasycarpus 6-9%, Alpinia oxyphylla 6-9%, Poria cocos 9-14%, Magnolia officinalis 6-9%.

[0013] The pharmaceutical composition of the present invention, wherein the optimal ratio of the active pharmaceutical ingredient is:

[0014] Astragalus membranaceus 23%, stir-fried Atractylodes macrocephala 9%, Smilax glabra 23%, Cynanchum paniculatum 9%, Dictamnus dasycarpus 8%, Alpinia oxyphylla 8%, Poria cocos 12%, Magnolia officinalis 8%.

[0015] The pharmaceutical composition of the present invention, wherein the active ingredient is obtained by the following method:

[0016] (1) Take the raw material and add 12 times the amount of water to decoct for 2 hours, filter, add 10 times the amount of water to the residue and decoct for 2 hours, filter, combine the two decoctions, and concentrate under reduced pressure to a solution with a relative density of 1 g / mL at 25°C to obtain the active ingredient.

[0017] The pharmaceutical composition described in this invention is a conventional compound, granule, tablet or capsule.

[0018] Atopic dermatitis can occur at any age, and can be divided into infancy, childhood, and adulthood. Adult-onset cases often have a long history of the disease, with most skin lesions being dry, thickened dermatitis, and intense itching, frequently leading to long-term anxiety and insomnia. Adult-onset atopic dermatitis often presents with a "dampness inside and dryness outside" condition; that is, the external skin manifestations are dry and scaly, while internal symptoms commonly include loose stools, a swollen tongue with teeth marks, and a slippery tongue coating. The inventors believe this is due to spleen deficiency, which impairs the transformation and transportation of dampness, leading to dampness accumulating internally and preventing the qi and blood from nourishing the skin, resulting in persistent dry and itchy skin. This condition is classified as "spleen deficiency with dampness accumulation," and treatment should focus on strengthening the spleen and eliminating dampness, supplemented by calming the mind and relieving itching.

[0019] Based on this, the inventor created this formula. The formula uses Astragalus membranaceus and stir-fried Atractylodes macrocephala as the principal ingredients: Astragalus membranaceus is sweet and warm in nature, and while tonifying the spleen and replenishing qi, it can also guide the qi and blood of the middle jiao upwards to moisturize the body surface and resolve the main symptom of dry and flaky skin; Stir-fried Atractylodes macrocephala is bitter, pungent, sweet, and warm in nature, and can promote the healthy functioning of the spleen and stomach to transform internal dampness. The combination of Astragalus membranaceus and stir-fried Atractylodes macrocephala, while tonifying, also promotes circulation, both replenishing the deficiencies of the spleen and stomach and strengthening the transformation and transportation of dampness, mutually reinforcing each other and addressing the core of the pathogenesis. This formula also uses Smilax glabra, Cynanchum paniculatum, and Dictamnus dasycarpus as assistant herbs. Smilax glabra is sweet and bland in taste and neutral in nature, and its function is to remove dampness and detoxify. It is good at draining dampness from the stomach and does not deplete qi. Cynanchum paniculatum is pungent and slightly warm in nature, and Dictamnus dasycarpus is bitter and cold in nature. Both of them have the effect of dispelling wind and relieving itching. Moreover, the pungent nature of Cynanchum paniculatum disperses dampness, and the bitter nature of Dictamnus dasycarpus dries dampness, which can promote the elimination of water and dampness in the middle jiao. The three herbs work together to transform water and dampness in the body and relieve itching symptoms. This formula also uses Alpinia oxyphylla and Poria cocos as adjuvant herbs. Alpinia oxyphylla is pungent and warm in nature, and its function is to warm the spleen and stop diarrhea, so as to assist the chief herb Astragalus membranaceus in warming and transforming water and dampness. Poria cocos is sweet and bland in taste and neutral in nature. It can strengthen the spleen and drain dampness, and also calm the mind and soothe the nerves, so as to improve insomnia symptoms. Magnolia officinalis is used as the guiding herb in this formula: it is bitter and pungent in taste and warm in nature. It is good at drying dampness and lowering qi, and can dredge the qi mechanism of the spleen and stomach so as to promote the flow of qi and the transformation of dampness. In addition, since it is made from tree bark, it is used to "use the bark to go to the skin" so as to concentrate the medicinal power of the whole formula on the skin surface. Therefore, it is used as the guiding herb.

[0020] Animal experiments

[0021] 1. Drugs and reagents:

[0022] Experimental group: the mixture described in Example 1 below;

[0023] Cetirizine hydrochloride tablets were purchased from Chongqing Huabang Pharmaceutical Co., Ltd.

[0024] 2,4-Dinitrofluorobenzene, purchased from Guangzhou Weijia Technology Co., Ltd.

[0025] Acetone, purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd.

[0026] Experimental animals: 32 Balb / C mice, weighing 18-22g, were purchased from Guangdong Provincial Medical Animal Experiment Center;

[0027] Experimental instruments: AUY120 SHIMADZU analytical balance, Guangzhou Xiangyi Electromechanical Equipment Co., Ltd.; MEGAFUGE2.0R low-temperature high-speed centrifuge, Hermle GmbH, Germany; vortex mixer, Shanghai Qingpu Huxi Instrument Factory;

[0028] 2 Experimental Methods

[0029] 2.1 Methods for establishing a model of atopic dermatitis with spleen deficiency and dampness syndrome

[0030] A 1% or 0.5% DNFB solution was prepared by adding acetone and DNFB powder. 200 μL of DNFB solution was dripped onto the back of mice in the model group and the atopic dermatitis spleen deficiency and dampness syndrome group using a syringe, while 20 μL of DNFB solution was dripped into the right ear to induce atopic dermatitis. 1% DNFB solution was administered once each on days 1 and 5, and 0.5% DNFB solution was started on day 7, with 200 μL and 20 μL of DNFB solution dripped onto the back and right ear of mice every other day. The control group received 200 μL and 20 μL of the matrix solution dripped onto the back and right ear, respectively. 200 μL of senna leaf decoction was administered by gavage every other day.

[0031] 2.2 Animal grouping and administration methods

[0032] Thirty-two mice were randomly divided into four groups: control group, model group, cetirizine hydrochloride group, and experimental group, with eight mice in each group. Based on the equivalent dose conversion for experimental animals, the cetirizine hydrochloride group was administered 1 mg / kg by gavage, the experimental group was administered 25.8 g / kg (crude drug amount) by gavage, and the blank control group and model group were treated with the same dose of physiological saline. The treatment was carried out continuously for 28 days.

[0033] 2.3 Severity of skin damage and skin lesion score

[0034] Before sampling on day 28, the skin damage on the ears and backs of mice in each group was observed according to the SCORAD scoring criteria, including erythema, edema, desquamation, and crusting, and was scored as follows: none (0 points), mild (1 point), moderate (2 points), severe (3 points), and very severe (4 points).

[0035] 2.4 General condition, abdominal circumference and body weight (evaluation indicators for spleen deficiency and dampness syndrome)

[0036] Observe the spontaneous activity and weight of mice in each group. The following symptoms will appear in the spleen deficiency and dampness syndrome: weight loss, increased abdominal girth, lethargy, poor skin texture, and easy fatigue.

[0037] 2.5 Spleen Index (Evaluation Index for Spleen Deficiency and Dampness Accumulation Syndrome)

[0038] After removing the spleen, rinse it thoroughly with saline solution, blot it dry with filter paper, and weigh it. Spleen index = spleen mass (mg) / body mass (g). An elevated spleen index will be observed in cases of spleen deficiency and dampness accumulation.

[0039] 2.6 24-hour food intake (evaluation index for spleen deficiency and dampness syndrome)

[0040] Poor appetite is one of the main manifestations of spleen qi deficiency syndrome in traditional Chinese medicine, and in mice, it often manifests as reduced food intake. 24-hour food intake (g / mouse) = (previous day's feed weight - current day's feed weight) / number of mice per cage.

[0041] 2.7 HE staining and epidermal thickness measurement of mouse dorsal / right ear skin

[0042] Skin lesions measuring 2 cm × 2 cm were excised from the back of mice or from the right ear of a mouse. These tissues were fixed in 4% paraformaldehyde solution, dehydrated, embedded, and then sectioned in paraffin to a thickness of 4 μm. After dewaxing and hydration, the sections were stained with hematoxylin and eosin, mounted, and observed under a microscope for pathological changes in the skin tissue. Epidermal thickness was measured using ImageJ software.

[0043] 2.8 Statistical Methods

[0044] Results are expressed as mean ± standard deviation (Mean ± SD). Data were compared using one-way ANOVA to determine statistical significance, with P < 0.05 considered statistically significant.

[0045] 3. Results:

[0046] 3.1 General condition, abdominal circumference, and body weight of mice in each group

[0047] Compared with the control group, the model group mice showed increased abdominal circumference and significantly decreased body weight, consistent with the characteristics of mice with spleen deficiency and dampness syndrome. Furthermore, with increasing modeling time, the mice exhibited lethargy, poor skin texture, and easy fatigue, with soft, wet, or even loose stools. However, after treatment with cetirizine hydrochloride tablets and the experimental group, the abdominal circumference significantly decreased and body weight significantly increased, indicating that the experimental group effectively improved the general condition, abdominal circumference, and body weight of mice with atopic dermatitis and spleen deficiency and dampness syndrome, and the stool gradually became more formed (see Table 1).

[0048] Table 1 Comparison of mouse body weight among groups

[0049] Group Waist circumference (cm) Body weight (g) control group 7.67±0.22 25.08±0.95 Model group <![CDATA[9.17±0.28 ## ]]> <![CDATA[22.29±2.44 ### ]]> cetirizine hydrochloride group <![CDATA[7.61±0.25 * ]]> <![CDATA[24.88±1.04 * ]]> experimental group <![CDATA[7.66±0.2 * ]]> <![CDATA[25±0.99 ** ]]>

[0050] Note: Compared with the model group, ## P < 0.01, ### P < 0.001; compared with the cetirizine hydrochloride group and the control group, * P < 0.05, ** P < 0.01.

[0051] 3.2 Results of changes in food intake of mice in each group over 24 hours

[0052] Compared with the control group, the model group mice had a significantly reduced 24-hour food intake, which is consistent with the reduced appetite of mice with spleen deficiency and dampness syndrome. After treatment with cetirizine hydrochloride tablets and the experimental group, the food intake increased significantly, indicating that the experimental group effectively improved the symptoms of reduced food intake in mice with atopic dermatitis and spleen deficiency and dampness syndrome, as shown in Table 2.

[0053] Table 2 Comparison of food intake in each group of mice over 24 hours

[0054] Group 24-hour food intake (g) control group 3.61±0.15 Model group <![CDATA[2.9±0.05 ## ]]> cetirizine hydrochloride group <![CDATA[3.54±0.19 * ]]> experimental group <![CDATA[3.55±0.18 * ]]>

[0055] Note: Compared with the model group, ## P < 0.01; compared with the cetirizine hydrochloride group and the control group, * P < 0.05.

[0056] 3.3 Differences in ear weight and pathological ear changes in each group of mice

[0057] Compared with the control group mice, the model group mice showed a significant increase in right ear weight, and pathological results showed that the epidermis of the right ear of the model group mice was thickened, with a large number of inflammatory cells infiltrating the dermis and obvious vasodilation, indicating a high level of inflammation in the right ear, consistent with the disease characteristics of atopic dermatitis mice. After treatment with cetirizine hydrochloride tablets and the experimental group, the inflammation level of the right ear decreased significantly, and the epidermal thickness decreased. Figure 1 The results show that the experimental group can effectively improve the level of ear inflammation in mice with atopic dermatitis and spleen deficiency with dampness accumulation syndrome, as shown in Table 3.

[0058] Table 3. Results of ear weight and epidermal thickness in each group of mice.

[0059] Group Weight difference between the two ears (mg) Right ear skin thickness (um) control group 5.63±2.076 31.5±4.68 Model group <![CDATA[29.5±3.42 ### ]]> <![CDATA[118.1±22.9 #### ]]> cetirizine hydrochloride group <![CDATA[22±2.07 * ]]> <![CDATA[62.6±94.97 ** ]]> experimental group <![CDATA[19.5±2.45 ** ]]> <![CDATA[62.3±5.18 ** ]]>

[0060] Note: Compared with the model group, ### P < 0.001, #### P < 0.0001; compared with the control group, * P < 0.05, ** P < 0.01.

[0061] 3.4 Dermatitis scores on the backs of mice in each group and morphological results of HE staining of skin tissue

[0062] The severity of dorsal dermatitis in each group of mice was assessed according to the skin lesion scoring criteria. On day 28, obvious skin lesions appeared on the backs of mice in the model group, including erythema, skin edema raised above the normal skin surface, and scaling. Figure 2 HE results showed that the model group mice had thickened skin spinosum, elongated epidermal ridges, and extensive infiltration of inflammatory cells. Figure 3 After treatment with cetirizine hydrochloride tablets and the experimental group, symptoms such as edema, erythema and scaling were significantly reduced, the epidermal thickness decreased, the epidermal lesion shortened, and the inflammatory cell infiltration decreased, indicating that the experimental group could effectively improve the skin lesions on the back of mice with atopic dermatitis due to spleen deficiency and dampness (see Table 4).

[0063] Table 4. Skin lesion scores and HE staining results of mice in each group on day 28.

[0064] Group Skin lesion score Epidermal thickness (µm) control group 0.39±0.25 33.12±6.13 Model group <![CDATA[8.56±0.32 ### ]]> <![CDATA[176.63±4.33 ### ]]> cetirizine hydrochloride group <![CDATA[5.83±0.31 ** ]]> <![CDATA[85.16±4.51 ** ]]> experimental group <![CDATA[6.86±0.33 * ]]> <![CDATA[93.78±2.83 * ]]>

[0065] Note: Compared with the model group, ### P < 0.001; compared with the blank control group, * P < 0.05; compared with the cetirizine hydrochloride group, ** P < 0.01.

[0066] 4. Conclusion

[0067] This study established a mouse model of atopic dermatitis with spleen deficiency and dampness accumulation syndrome, and investigated the therapeutic effects of experimental drugs on this syndrome. Results showed that after modeling, mice exhibited increased abdominal circumference, significant weight loss, significantly reduced 24-hour food intake, lethargy, poor skin texture, and fatigue. Their stools were soft and watery, consistent with the characteristics of mice with spleen deficiency and dampness accumulation syndrome. After treatment, the weight of the mice's ears and the thickness of the epidermis significantly decreased. Edema, erythema, and scaling on the back lesions were significantly reduced, and epidermal thickness and inflammatory cell infiltration were decreased. These results indicate that the experimental group had an ameliorative effect on atopic dermatitis with spleen deficiency and dampness accumulation syndrome. Attached Figure Description

[0068] Figure 1 Microscopic images of the pathological tissue of the right ear of mice in each group.

[0069] Figure 2 Photos of skin lesions on the backs of mice in each group on day 28.

[0070] Figure 3 Microscopic images of HE-stained skin tissue from each group of mice. Detailed Implementation

[0071] Example 1 (Mixed Solution)

[0072] 1. Prescription:

[0073] Astragalus membranaceus 297g, stir-fried Atractylodes macrocephala 116g, Smilax glabra 297g, Cynanchum paniculatum 116g, Dictamnus dasycarpus 103g, Alpinia oxyphylla 103g, Poria cocos 155g, Magnolia officinalis 103g.

[0074] 2. Preparation method:

[0075] (1) Take the drug and add 12 times the amount of water to decoct for 2 hours, filter, add 10 times the amount of water to the residue and decoct for 2 hours, filter, combine the decoctions, and concentrate under reduced pressure to a solution with a relative density of 1 g / mL at 25°C.

[0076] (2) Take the solution obtained in step (1), add flavoring agent, sterilize, and dispense into 100mL / bottle.

[0077] Example 2 (Granules)

[0078] 1. Prescription:

[0079] Astragalus membranaceus 297g, stir-fried Atractylodes macrocephala 116g, Smilax glabra 297g, Cynanchum paniculatum 116g, Dictamnus dasycarpus 103g, Alpinia oxyphylla 103g, Poria cocos 155g, Magnolia officinalis 103g.

[0080] 2. Preparation method:

[0081] (1) Take the medicine and add 12 times the amount of water to decoct for 2 hours, filter, add 10 times the amount of water to the residue and decoct for 2 hours, filter, combine the decoctions, concentrate under reduced pressure to a solution with a relative density of 1 g / mL at 25°C, and then further concentrate under reduced pressure to a thick paste with a relative density of 1.30.

[0082] (2) Take the thick paste obtained in step (1), vacuum dry it to obtain dry paste powder, add excipients to granulate, then dry and granulate, and package it into 10g / packet.

[0083] Example 3 (Mixed Solution)

[0084] 1. Prescription:

[0085] Astragalus membranaceus 355g, stir-fried Atractylodes macrocephala 129g, Smilax glabra 296g, Cynanchum paniculatum 103g, Dictamnus dasycarpus 81g, Alpinia oxyphylla 81g, Poria cocos 142g, Magnolia officinalis 103g.

[0086] 2. Preparation method:

[0087] Same as Example 1.

[0088] Example 4 (Granules)

[0089] 1. Prescription:

[0090] Astragalus membranaceus 249g, stir-fried Atractylodes macrocephala 104g, Smilax glabra 300g, Cynanchum paniculatum 130g, Dictamnus dasycarpus 117g, Alpinia oxyphylla 117g, Poria cocos 169g, Magnolia officinalis 104g.

[0091] 2. Preparation method:

[0092] Same as Example 2.

[0093] Example 5 (Mixed Solution)

[0094] Astragalus membranaceus 326g, stir-fried Atractylodes macrocephala 117g, Smilax glabra 275g, Cynanchum paniculatum 104g, Dictamnus dasycarpus 91g, Alpinia oxyphylla 104g, Poria cocos 169g, Magnolia officinalis 104g.

[0095] 2. Preparation method:

[0096] Same as Example 1.

[0097] Example 6 (Capsule Formulation)

[0098] The granules were prepared according to the method in Example 2, and then filled into gelatin capsules to form capsules.

[0099] Example 7 (tablet)

[0100] Granules were prepared according to the method in Example 2. Sugar powder was added, and 95% ethanol was used as a wetting agent to make a soft mass. The mass was granulated by passing it through a 16-mesh sieve, dried, and compressed into tablets using conventional methods.

Claims

1. A pharmaceutical composition for treating adult atopic dermatitis of the spleen-deficiency and dampness-retention type, the pharmaceutical composition comprising an active ingredient and medically acceptable excipients, wherein said active ingredient is made from the following raw material in weight percentages: Astragalus membranaceus 19-28%, stir-fried Atractylodes macrocephala 8-11%, Smilax glabra 19-28%, Cynanchum paniculatum 8-11%, Dictamnus dasycarpus 6-9%, Alpinia oxyphylla 6-9%, Poria cocos 9-14%, Magnolia officinalis 6-9%.

2. The pharmaceutical composition for treating adult atopic dermatitis of spleen deficiency and dampness retention type according to claim 1, characterized in that, The active ingredient is made from the following raw materials by weight percentage: Astragalus membranaceus 23%, stir-fried Atractylodes macrocephala 9%, Smilax glabra 23%, Cynanchum paniculatum 9%, Dictamnus dasycarpus 8%, Alpinia oxyphylla 8%, Poria cocos 12%, Magnolia officinalis 8%.

3. A pharmaceutical composition for treating adult atopic dermatitis of spleen deficiency and dampness retention type according to claim 1 or 2, characterized in that, The active ingredient is obtained by the following method: (1) Take the raw material and add 12 times the amount of water to decoct for 2 hours, filter, add 10 times the amount of water to the residue and decoct for 2 hours, filter, combine the two decoctions, and concentrate under reduced pressure to a solution with a relative density of 1g / mL at 25℃ to obtain the active ingredient.

4. The pharmaceutical composition for treating adult atopic dermatitis of spleen deficiency and dampness retention type according to claim 3, characterized in that, The traditional Chinese medicine composition is in the form of a mixture, granules, tablets, or capsules.

Images